Perfil antiinflamatorio del Paricalcitol (cas 131918-61-1) en el receptor de trasplante renal
-
Add time:07/29/2019 Source:sciencedirect.com
ResumenAntecedentes y objetivosEl Paricalcitol (cas 131918-61-1), un activador selectivo del receptor de la vitamina D, se utiliza en el tratamiento del hiperparatiroidismo secundario en el receptor de trasplante renal. Estudios tanto clínicos como experimentales realizados en pacientes renales no trasplantados muestran propiedades antiinflamatorias para esta molécula. En este estudio exploratorio, hemos evaluado el perfil antiinflamatorio del paricalcitol en receptores de trasplante renal.
We also recommend Trading Suppliers and Manufacturers of Paricalcitol (cas 131918-61-1). Pls Click Website Link as below: cas 131918-61-1 suppliers
Prev:Vitamin D receptor activation by Paricalcitol (cas 131918-61-1) and insulin resistance in CKD
Next:Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol (cas 131918-61-1)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Effect of Paricalcitol (cas 131918-61-1) on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism08/02/2019
- Effects of oral Paricalcitol (cas 131918-61-1) therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism08/01/2019
- Paricalcitol (cas 131918-61-1) Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients07/31/2019
- Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol (cas 131918-61-1)07/30/2019
- Vitamin D receptor activation by Paricalcitol (cas 131918-61-1) and insulin resistance in CKD07/28/2019
- Paricalcitol (cas 131918-61-1) alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation07/27/2019
- Anti-inflammatory profile of Paricalcitol (cas 131918-61-1) in kidney transplant recipients07/26/2019